

Proposed Bill for Medicaid Coverage of Certain Fertility Drugs

Healthcare Law Update

Proposed Bill for Medicaid Coverage of Certain Fertility Drugs

John D. Fanburg
Managing Member & Chair, Healthcare

Edward Hilzenrath
Member, Healthcare

Rebecca T. Falk
Associate, Healthcare

BRACH | EICHLER^{LLC}
Counsellors at Law

5/1/2025

[Senate Bill 4294](#), introduced in the New Jersey Senate on March 24, 2025, would require Medicaid to cover ovulation enhancing drugs and the medical services related to administering such drugs for certain beneficiaries who are experiencing infertility. The scope of the Bill would apply to medical services related to prescribing and monitoring the use of such drugs for individuals 21 through 44 years of age if there is federal financial participation available. Medical services covered under the bill would be limited to office visits, hysterosalpingograms, pelvic ultrasounds, and blood testing.

[Click Here to read the entire May 2025 Healthcare Law Update now!](#)

For more information, contact:

John D. Fanburg, Chair | 973.403.3107 | jfanburg@bracheichler.com

Edward Hilzenrath | 973.403.3114 | ehilzenrath@bracheichler.com

Rebecca T. Falk | 973.364.8393 | rfalk@bracheichler.com

Authors

The following attorneys contributed to this insight.



John D. Fanburg

Managing Member
Healthcare Law, Cannabis Industry
973.403.3107 • 973.618.5507 Fax
jfanburg@bracheichler.com



Edward Hilzenrath

Member
Healthcare Law
973.403.3114 • 973.618.5594 Fax
ehilzenrath@bracheichler.com



Rebecca T. Falk

Associate
Healthcare Law
973-364-8393 • 973-618-5923 Fax
rfalk@bracheichler.com